{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T14:24:17Z","timestamp":1788531857855,"version":"build-2803163510"},"reference-count":103,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      The management of multidrug-resistant (MDR)\n                      <jats:italic>Pseudomonas aeruginosa<\/jats:italic>\n                      has evolved from an antibiotic-centric approach to a mechanism-driven paradigm. Among resistance determinants, metallo-\u03b2-lactamases (MBLs) represent a critical challenge due to their ability to hydrolyse most \u03b2-lactams and their increasing global dissemination within high-risk clones.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This narrative review aims to summarize the epidemiology, diagnostic approaches and therapeutic strategies for infections caused by MBL-producing\n                      <jats:italic>P. aeruginosa<\/jats:italic>\n                      , emphasizing a mechanism-based clinical framework. A PubMed-MEDLINE search was conducted up to 1 June 2026 using the terms \u201c\n                      <jats:italic>Pseudomonas aeruginosa<\/jats:italic>\n                      \u201d, \u201c\n                      <jats:italic>carbapenem resistance<\/jats:italic>\n                      \u201d, and \u201c\n                      <jats:italic>metallo-<\/jats:italic>\n                      \u03b2\n                      <jats:italic>-lactamase<\/jats:italic>\n                      \u201d. Relevant studies were selected based on the authors' assessment of methodological quality and clinical relevance.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      <jats:italic>P. aeruginosa<\/jats:italic>\n                      exhibits multifactorial resistance involving intrinsic mechanisms (efflux pumps, AmpC overexpression, porin loss), adaptive responses and acquired carbapenemases. MBLs, especially VIM, IMP, and emerging NDM variants, are increasingly associated with carbapenem resistance and epidemic high-risk clones (e.g., ST235, ST111). Global epidemiology shows marked geographic variability in prevalence and molecular types. Diagnostic workup remains challenging due to the coexistence of enzymatic and non-enzymatic mechanisms, requiring integrated use of phenotypic antibiotic susceptibility testing (AST), carbapenemase detection assays, molecular diagnostics, and, in selected cases, whole-genome sequencing (WGS). Among treatment, cefiderocol represents the most evidence-supported option for MBL-producing strains. Aztreonam-based combinations offer an alternative treatment option, provided susceptibility is confirmed by synergy testing. Emerging antimicrobials (e.g., taniborbactam-, xeruborbactam-, and zidebactam-containing regimens) and novel strategies such as bacteriophage therapy are regarded as promising alternatives. Evidence for combination therapy remains limited and should be individualized.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      MBL-producing\n                      <jats:italic>P. aeruginosa<\/jats:italic>\n                      requires an integrated, mechanism-based diagnostic and therapeutic strategy incorporating local epidemiology, rapid diagnostics and optimized antimicrobial selection. Ongoing development of novel agents and precision microbiology tools is expected to further refine clinical management.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmicb.2026.1924442","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T13:51:29Z","timestamp":1788529889000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Metallo-\u03b2-lactamase-producing Pseudomonas aeruginosa: epidemiology, diagnostic challenges and therapeutic strategies in the era of MDR\/XDR resistance"],"prefix":"10.3389","volume":"17","author":[{"given":"Alessandra","family":"Imeneo","sequence":"first","affiliation":[{"name":"Systemic and Immune Depression-Associated Infections Unit, National Institute for Infectious Diseases \u201cLazzaro Spallanzani\u201d, IRCCS","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Capone","sequence":"additional","affiliation":[{"name":"Systemic and Immune Depression-Associated Infections Unit, National Institute for Infectious Diseases \u201cLazzaro Spallanzani\u201d, IRCCS","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Antonelli","sequence":"additional","affiliation":[{"name":"Microbiology and Biobank Unit, National Institute for Infectious Diseases \u201cLazzaro Spallanzani\u201d, IRCCS","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Perri","sequence":"additional","affiliation":[{"name":"Microbiology and Biobank Unit, National Institute for Infectious Diseases \u201cLazzaro Spallanzani\u201d, IRCCS","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivano","family":"Petriccione","sequence":"additional","affiliation":[{"name":"Microbiology and Biobank Unit, National Institute for Infectious Diseases \u201cLazzaro Spallanzani\u201d, IRCCS","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Lodi","sequence":"additional","affiliation":[{"name":"Systemic and Immune Depression-Associated Infections Unit, National Institute for Infectious Diseases \u201cLazzaro Spallanzani\u201d, IRCCS","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Fontana","sequence":"additional","affiliation":[{"name":"Microbiology and Biobank Unit, National Institute for Infectious Diseases \u201cLazzaro Spallanzani\u201d, IRCCS","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Cicalini","sequence":"additional","affiliation":[{"name":"Systemic and Immune Depression-Associated Infections Unit, National Institute for Infectious Diseases \u201cLazzaro Spallanzani\u201d, IRCCS","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e114","DOI":"10.1017\/S0950268825100332","article-title":"Worldwide threatening prevalence of carbapenem-resistant Pseudomonas aeruginosa","volume":"153","author":"Ahmadi","year":"2025","journal-title":"Epidemiol. Infect."},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.12669\/pjms.37.7.4303","article-title":"Genetic diversity molecular analysis of metallo beta lactamases among imipenem resistant clinical isolates of Pseudomonas aeruginosa from Peshawar, Pakistan","author":"Ali","year":""},{"key":"B3","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial","volume":"21","author":"Bassetti","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"B4","doi-asserted-by":"publisher","first-page":"652","DOI":"10.3390\/antibiotics10060652","article-title":"Cefiderocol-based combination therapy for \u201cdifficult-to-treat\u201d gram-negative severe infections: real-life case series and future perspectives","volume":"10","author":"Bavaro","year":"2021","journal-title":"Antibiotics"},{"key":"B5","doi-asserted-by":"publisher","first-page":"107311","DOI":"10.1016\/j.mimet.2025.107311","article-title":"Evaluating the susceptibility of MBL carbapenemase-producing Enterobacteriaceae and Pseudomonas spp. to ceftazidime\/avibactam plus aztreonam and cefiderocol: a synergy study and susceptibility profile","volume":"239","author":"Blanco","year":"2025","journal-title":"J. Microbiol. Methods"},{"key":"B6","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/s41576-019-0108-4","article-title":"Sequencing-based methods and resources to study antimicrobial resistance","volume":"20","author":"Boolchandani","year":"2019","journal-title":"Nat. Rev. Genet."},{"key":"B7","doi-asserted-by":"publisher","first-page":"100640","DOI":"10.1016\/j.drup.2019.07.002","article-title":"Antibiotic resistance in Pseudomonas aeruginosa\u2014mechanisms, epidemiology and evolution","volume":"44","author":"Botelho","year":"2019","journal-title":"Drug Resist. Updat."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1038\/s41591-025-03678-8","article-title":"Personalized inhaled bacteriophage therapy for treatment of multidrug-resistant Pseudomonas aeruginosa in cystic fibrosis","volume":"31","author":"Chan","year":"2025","journal-title":"Nat. Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/S1473-3099(11)70056-1","article-title":"Metallo-\u03b2-lactamases: a last frontier for \u03b2-lactams?","volume":"11","author":"Cornaglia","year":"2011","journal-title":"Lancet Infect. Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13054-025-05266-1","article-title":"Incidence of hospital-acquired infections due to carbapenem-resistant Enterobacterales and Pseudomonas aeruginosa in critically ill patients in Italy: a multicentre prospective cohort study","volume":"29","author":"De Pascale","year":"2025","journal-title":"Crit. Care"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e01589","DOI":"10.1128\/AAC.01589-17","article-title":"Genomics and Susceptibility Profiles of Extensively Drug-Resistant Pseudomonas aeruginosa Isolates from Spain","volume":"61","author":"Del Barrio-Tofi\u00f1o","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"B12","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/nrg3226","article-title":"Transforming clinical microbiology with bacterial genome sequencing","volume":"13","author":"Didelot","year":"2012","journal-title":"Nat. Rev. Genet."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e0308022","DOI":"10.1128\/spectrum.03080-22","article-title":"In vivo development of aztreonam resistance in meropenem-resistant Pseudomonas aeruginosa owing to overexpression of the blaPDC-16","volume":"11","author":"Ding","year":"2023","journal-title":"Microbiol. Spectr."},{"key":"B14","doi-asserted-by":"publisher","first-page":"dlaf249","DOI":"10.1093\/jacamr\/dlaf249","article-title":"An improved algorithm to screen for carbapenemase production in Pseudomonas aeruginosa","volume":"8","author":"Ellem","year":"2026","journal-title":"JAC Antimicrob. Resist."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.cmi.2016.11.012","article-title":"The role of whole genome sequencing in antimicrobial susceptibility testing of bacteria: report from the EUCAST Subcommittee","volume":"23","author":"Ellington","year":"2017","journal-title":"Clin. Microbiol. Infect."},{"key":"B16","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1097\/QCO.0000000000001044","article-title":"Not all carbapenem-resistant Pseudomonas aeruginosa strains are alike: tailoring antibiotic therapy based on resistance mechanisms","volume":"37","author":"Falcone","year":"2024","journal-title":"Curr. Opin. Infect. Dis."},{"key":"B17","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s10096-024-04752-8","article-title":"Molecular analysis of metallo-beta-lactamase-producing Pseudomonas aeruginosa in Switzerland 2022\u20132023","volume":"43","author":"Findlay","year":"2024","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"106788","DOI":"10.1016\/j.ijantimicag.2023.106788","article-title":"Insight into phylogenomic bias of blaVIM-2 or blaNDM-1 dissemination amongst carbapenem-resistant Pseudomonas aeruginosa","volume":"61","author":"Fortunato","year":"2023","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B19","doi-asserted-by":"publisher","first-page":"ofab617","DOI":"10.1093\/ofid\/ofab617","article-title":"Multicenter, prospective validation of a phenotypic algorithm to guide carbapenemase testing in carbapenem-resistant Pseudomonas aeruginosa using the ERACE-PA Global Surveillance Program","volume":"9","author":"Gill","year":"2022","journal-title":"Open Forum Infect. Dis."},{"key":"B20","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1093\/jac\/dkad396","article-title":"In vitro activity of cefiderocol against a global collection of carbapenem-resistant Pseudomonas aeruginosa with a high level of carbapenemase diversity","volume":"79","author":"Gill","year":"2024","journal-title":"J. Antimicrob. Chemother."},{"key":"B21","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1093\/jac\/dkad032","article-title":"In vivo efficacy and resistance prevention of cefiderocol in combination with ceftazidime\/avibactam, ampicillin\/sulbactam or meropenem using human-simulated regimens versus Acinetobacter baumannii","volume":"78","author":"Gill","year":"2023","journal-title":"J. Antimicrob. Chemother."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e01888","DOI":"10.1128\/mBio.01888-15","article-title":"Making the leap from research laboratory to clinic: challenges and opportunities for next-generation sequencing in infectious disease diagnostics","volume":"6","author":"Goldberg","year":"2015","journal-title":"mBio"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1093\/jac\/dkad172","article-title":"In vitro dynamics and mechanisms of cefiderocol resistance development in wild-type, mutator and XDR Pseudomonas aeruginosa","volume":"78","author":"Gomis-Font","year":"2023","journal-title":"J. Antimicrob. Chemother."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1093\/jac\/dkae263","article-title":"Impact of chromosomally encoded resistance mechanisms and transferable \u03b2-lactamases on the activity of cefiderocol and innovative \u03b2-lactam\/\u03b2-lactamase inhibitor combinations against Pseudomonas aeruginosa","volume":"79","author":"Gonz\u00e1lez-Pinto","year":"2024","journal-title":"J. Antimicrob. Chemother."},{"key":"B25","doi-asserted-by":"publisher","first-page":"210","DOI":"10.3390\/antibiotics14020210","article-title":"Combating metallo-\u03b2-lactamase-producing Pseudomonas aeruginosa: the fractional inhibitory concentration index as a tool to evaluate antibiotic synergy","volume":"14","author":"Granata","year":"2025","journal-title":"Antibiotics"},{"key":"B26","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s44259-024-00033-8","article-title":"Limitations of current techniques in clinical antimicrobial resistance diagnosis: examples and future prospects","volume":"2","author":"Hassall","year":"2024","journal-title":"NPJ Antimicrob. Resist."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e02161","DOI":"10.1128\/aac.02161-21","article-title":"In vitro activity of cefepime-taniborbactam against carbapenemase-producing Enterobacterales and Pseudomonas aeruginosa isolates recovered in Spain","volume":"66","author":"Hern\u00e1ndez-Garc\u00eda","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1007\/s40265-024-02102-8","article-title":"The challenge of treating infections caused by metallo-\u03b2-lactamase-producing gram-negative bacteria: a narrative review","volume":"84","author":"Hidalgo-Tenorio","year":"2024","journal-title":"Drugs"},{"key":"B29","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s12866-023-02864-3","article-title":"Relebactam restores susceptibility of resistant Pseudomonas aeruginosa and Enterobacterales and enhances imipenem activity against chromosomal AmpC-producing species: analysis of global SMART 2018-2020","volume":"23","author":"Hilbert","year":"2023","journal-title":"BMC Microbiol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"81","DOI":"10.3947\/ic.2015.47.2.81","article-title":"Epidemiology and characteristics of metallo-\u03b2-lactamase-producing Pseudomonas aeruginosa","volume":"47","author":"Hong","year":"2015","journal-title":"Infect. Chemother."},{"key":"B31","doi-asserted-by":"publisher","first-page":"e00031","DOI":"10.1128\/CMR.00031-19","article-title":"Epidemiology and treatment of multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa infections","volume":"32","author":"Horcajada","year":"2019","journal-title":"Clin. Microbiol. Rev."},{"key":"B32","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.idc.2025.11.001","article-title":"Current management strategies of difficult-to-treat resistant Pseudomonas aeruginosa infections","volume":"40","author":"Horcajada","year":"2026","journal-title":"Infect. Dis. Clin. North Am."},{"key":"B33","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.cll.2020.08.002","article-title":"Update on susceptibility testing: genotypic and phenotypic methods","volume":"40","author":"Humphries","year":"2020","journal-title":"Clin. Lab. Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1542491","DOI":"10.3389\/fmicb.2025.1542491","article-title":"Ceftolozane\/tazobactam use and emergence of resistance: a 4-year analysis of antimicrobial susceptibility in Pseudomonas aeruginosa isolates in a tertiary hospital","volume":"16","author":"Imeneo","year":"2025","journal-title":"Front. Microbiol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"e01454","DOI":"10.1128\/AAC.01454-17","article-title":"In vitro antibacterial properties of cefiderocol, a novel siderophore cephalosporin, against gram-negative bacteria","volume":"62","author":"Ito","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"B36","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1590\/0037-8682-0044-2018","article-title":"Prevalence of metallo-\u03b2-lactamase-encoding genes among carbapenem-resistant Pseudomonas aeruginosa strains isolated from burn patients in Iran","volume":"51","author":"Jabalameli","year":"2018","journal-title":"Rev. Soc. Bras. Med. Trop."},{"key":"B37","doi-asserted-by":"publisher","first-page":"371","DOI":"10.3389\/fcimb.2019.00371","article-title":"The rapid carbapenemase detection method (rCDM) for rapid and accurate detection of carbapenemase-producing enterobacteriaceae and Pseudomonas aeruginosa","volume":"9","author":"Jing","year":"2019","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"4215","DOI":"10.1128\/AAC.00493-13","article-title":"Sublethal ciprofloxacin treatment leads to rapid development of high-level ciprofloxacin resistance during long-term experimental evolution of Pseudomonas aeruginosa","volume":"57","author":"J\u00f8rgensen","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"B39","doi-asserted-by":"publisher","first-page":"e00517","DOI":"10.1128\/mBio.00517-17","article-title":"Evolved aztreonam resistance is multifactorial and can produce hypervirulence in Pseudomonas aeruginosa","volume":"8","author":"Jorth","year":"2017","journal-title":"mBio"},{"key":"B40","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1093\/jac\/dks439","article-title":"Challenges for accurate susceptibility testing, detection and interpretation of \u03b2-lactam resistance phenotypes in Pseudomonas aeruginosa: results from a Spanish multicentre study","volume":"68","author":"Juan","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"B41","doi-asserted-by":"publisher","first-page":"723","DOI":"10.3390\/antibiotics11060723","article-title":"Cefiderocol: systematic review of mechanisms of resistance, heteroresistance and in vivo emergence of resistance","volume":"11","author":"Karakonstantis","year":"2022","journal-title":"Antibiotics."},{"key":"B42","doi-asserted-by":"publisher","first-page":"e0207925","DOI":"10.1128\/spectrum.02079-25","article-title":"Activity of cefiderocol against Pseudomonas aeruginosa from the USA and Europe (2020\u20132023) with difficult-to-treat resistance phenotype, including those nonsusceptible to recently developed \u03b2-lactam\/\u03b2-lactamase inhibitor combinations: results from the SENTRY antimicrobial surveillance program","volume":"13","author":"Kimbrough","year":"2025","journal-title":"Microbiol. Spectr."},{"key":"B43","doi-asserted-by":"publisher","first-page":"e00857","DOI":"10.1128\/aac.00857-25","article-title":"Efficacy of cefiderocol in combination with xeruborbactam versus taniborbactam against cefiderocol-resistant NDM-producing Pseudomonas aeruginosa","volume":"69","author":"Kocer","year":"2025","journal-title":"Antimicrob. Agents Chemother."},{"key":"B44","doi-asserted-by":"publisher","first-page":"e01570","DOI":"10.1128\/aac.00991-23","article-title":"Relative inhibitory activities of the broad-spectrum \u03b2-lactamase inhibitor xeruborbactam in comparison with taniborbactam against metallo-\u03b2-lactamases produced in Escherichia coli and Pseudomonas aeruginosa","volume":"68","author":"Le Terrier","year":"2024","journal-title":"Antimicrob. Agents Chemother."},{"key":"B45","doi-asserted-by":"publisher","first-page":"S92","DOI":"10.1093\/infdis\/jiag033","article-title":"Challenges and strategies in managing \u03b2-lactam-resistant Pseudomonas aeruginosa in China","volume":"233","author":"Li","year":"2026","journal-title":"J. Infect. Dis."},{"key":"B46","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1128\/CMR.00040-09","article-title":"Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms","volume":"22","author":"Lister","year":"2009","journal-title":"Clin. Microbiol. Rev."},{"key":"B47","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1086\/338782","article-title":"Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare?","volume":"34","author":"Livermore","year":"2002","journal-title":"Clin. Infect. Dis."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1093\/cid\/ciaa122","article-title":"Carbapenem-resistant Enterobacterales, carbapenem resistant organisms, carbapenemase-producing Enterobacterales, and carbapenemase-producing organisms: terminology past its \u201csell-by date\u201d in an era of new antibiotics and regional carbapenemase epidemiology","volume":"71","author":"Livermore","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"B49","doi-asserted-by":"publisher","first-page":"e00440","DOI":"10.1128\/aac.00440-23","article-title":"In vitro potency of xeruborbactam in combination with multiple \u03b2-lactam antibiotics in comparison with other \u03b2-lactam\/\u03b2-lactamase inhibitor (BLI) combinations against carbapenem-resistant and extended-spectrum \u03b2-lactamase-producing Enterobacterales","volume":"67","author":"Lomovskaya","year":"2023","journal-title":"Antimicrob. Agents Chemother."},{"key":"B50","doi-asserted-by":"publisher","first-page":"538.e7","DOI":"10.1016\/j.cmi.2022.11.014","article-title":"Cefiderocol resistance genomics in sequential chronic Pseudomonas aeruginosa isolates from cystic fibrosis patients","volume":"29","author":"L\u00f3pez-Causap\u00e9","year":"2023","journal-title":"Clin. Microbiol. Infect."},{"key":"B51","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin. Microbiol. Infect."},{"key":"B52","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1089\/mdr.2023.0090","article-title":"In vitro activity of cefiderocol against carbapenem-resistant Enterobacterales and Pseudomonas aeruginosa","volume":"29","author":"Malisova","year":"2023","journal-title":"Microb. Drug Resist."},{"key":"B53","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1089\/mdr.2016.0012","article-title":"VIM-1, VIM-2, and GES-5 carbapenemases among Pseudomonas aeruginosa isolates at a tertiary hospital in Istanbul, Turkey","volume":"23","author":"Malko\u00e7oglu","year":"2017","journal-title":"Microb. Drug Resist."},{"key":"B54","doi-asserted-by":"publisher","first-page":"e0319624","DOI":"10.1128\/spectrum.03196-24","article-title":"Diagnostic algorithm for the detection of carbapenemases and extended-spectrum \u03b2-lactamases in carbapenem-resistant Pseudomonas aeruginosa","volume":"13","author":"Mancini","year":"2025","journal-title":"Microbiol. Spectr."},{"key":"B55","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3390\/antibiotics12010049","article-title":"Intravenous fosfomycin: a potential good partner for cefiderocol. clinical experience and considerations","volume":"12","author":"Marino","year":"2022","journal-title":"Antibiotics"},{"key":"B56","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1080\/14787210.2018.1441024","article-title":"Murepavadin: a new antibiotic class in the pipeline","volume":"16","author":"Martin-Loeches","year":"2018","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.3390\/antibiotics10081012","article-title":"The revival of aztreonam in combination with avibactam against metallo-\u03b2-lactamase-producing gram-negatives: a systematic review of in vitro studies and clinical cases","volume":"10","author":"Mauri","year":"2021","journal-title":"Antibiotics"},{"key":"B58","doi-asserted-by":"publisher","first-page":"e0217120","DOI":"10.1128\/AAC.02171-20","article-title":"New perspectives on antimicrobial agents: cefiderocol","volume":"65","author":"McCreary","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"B59","doi-asserted-by":"publisher","first-page":"e0023624","DOI":"10.1128\/aac.00236-24","article-title":"Patient outcomes by baseline pathogen resistance phenotype and genotype in CERTAIN-1, a phase 3 study of cefepime-taniborbactam versus meropenem in adults with complicated urinary tract infection","volume":"68","author":"Moeck","year":"2024","journal-title":"Antimicrob. Agents Chemother."},{"key":"B60","doi-asserted-by":"publisher","first-page":"13717","DOI":"10.1038\/s41598-020-70581-2","article-title":"Transcriptomic determinants of the response of ST-111 Pseudomonas aeruginosa AG1 to ciprofloxacin identified by a top-down systems biology approach","volume":"10","author":"Molina-Mora","year":"2020","journal-title":"Sci. Rep."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1007\/s10096-025-05061-4","article-title":"Addressing carbapenemase-producing extensively drug-resistant Pseudomonas aeruginosa: the potential of cefiderocol and ceftazidime\/avibactam plus aztreonam therapy","volume":"44","author":"Montero","year":"2025","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"B62","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jgar.2022.07.010","article-title":"Clinical and microbiological features of ceftolozane\/tazobactam-resistant Pseudomonas aeruginosa isolates in a university hospital in central Italy","volume":"30","author":"Morroni","year":"2022","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"B63","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.ijid.2021.05.085","article-title":"Combination of aztreonam, ceftazidime-avibactam and amikacin in the treatment of VIM-1 Pseudomonas aeruginosa ST235 osteomyelitis","volume":"108","author":"Mularoni","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1093\/jac\/dkab067","article-title":"Activity of cefepime\/zidebactam (WCK 5222) against \u2018problem' antibiotic-resistant gram-negative bacteria sent to a national reference laboratory","volume":"76","author":"Mushtaq","year":"2021","journal-title":"J. Antimicrob. Chemother."},{"key":"B65","doi-asserted-by":"publisher","first-page":"e00757","DOI":"10.1128\/AAC.00757-20","article-title":"In vitro activity of the ultrabroad-spectrum-beta-lactamase inhibitor QPX7728 against carbapenem-resistant Enterobacterales with varying intrinsic and acquired resistance mechanisms","volume":"64","author":"Nelson","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"B66","doi-asserted-by":"publisher","first-page":"e00932","DOI":"10.1128\/JCM.00932-20","article-title":"NitroSpeed-carba NP test for rapid detection and differentiation between different classes of carbapenemases in Enterobacterales","volume":"58","author":"Nordmann","year":"2020","journal-title":"J. Clin. Microbiol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1016\/j.cmi.2025.03.013","article-title":"Emerging resistance mechanisms to newer \u03b2-lactams in Pseudomonas aeruginosa","volume":"31","author":"Oliver","year":"2025","journal-title":"Clin. Microbiol. Infect."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1126\/science.288.5469.1251","article-title":"High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection","volume":"288","author":"Oliver","year":"2000","journal-title":"Science"},{"key":"B69","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.cmi.2023.12.026","article-title":"Pseudomonas aeruginosa antimicrobial susceptibility profiles, resistance mechanisms and international clonal lineages: update from ESGARS-ESCMID\/ISARPAE Group","volume":"30","author":"Oliver","year":"2024","journal-title":"Clin. Microbiol. Infect."},{"key":"B70","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3390\/medsci13010006","article-title":"Whole-genome sequencing of resistance, virulence and regulation genes in extremely resistant strains of Pseudomonas aeruginosa","volume":"13","author":"Pajaro-Castro","year":"2025","journal-title":"Med. Sci."},{"key":"B71","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.biotechadv.2018.11.013","article-title":"Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies","volume":"37","author":"Pang","year":"2019","journal-title":"Biotechnol. Adv."},{"key":"B72","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.3390\/jcm15051683","article-title":"Genomic insights into carbapenem-resistant Pseudomonas aeruginosa (CRPA): resistome and virulome analysis beyond carbapenemases","volume":"15","author":"Pantanella","year":"2026","journal-title":"J. Clin. Med."},{"key":"B73","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/S1473-3099(25)00469-4","article-title":"Cefiderocol versus standard therapy for hospital-acquired and health-care-associated gram-negative bacterial bloodstream infection (the GAME CHANGER trial): an open-label, parallel-group, randomised trial","volume":"26","author":"Paterson","year":"2026","journal-title":"Lancet Infect. Dis."},{"key":"B74","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant gram-negative bacilli (endorsed by European society of intensive care medicine)","volume":"28","author":"Paul","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"key":"B75","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1093\/jac\/dkaf083","article-title":"Ceftazidime-avibactam plus aztreonam cocktail for the treatment of VIM-producing Pseudomonas aeruginosa infections: good enough to have another?","volume":"80","author":"Pina-S\u00e1nchez","year":"2025","journal-title":"J. Antimicrob. Chemother."},{"key":"B76","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1128\/AAC.01953-12","article-title":"FIM-1, a new acquired metallo-\u03b2-lactamase from a Pseudomonas aeruginosa clinical isolate from Italy","volume":"57","author":"Pollini","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"B77","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/j.1469-0691.2004.00763.x","article-title":"Efflux-mediated multiresistance in gram-negative bacteria","volume":"10","author":"Poole","year":"2004","journal-title":"Clin. Microbiol. Infect."},{"key":"B78","doi-asserted-by":"publisher","first-page":"762","DOI":"10.3390\/antibiotics13080762","article-title":"Rapid reversal of carbapenemase-producing Pseudomonas aeruginosa epidemiology from blaVIM- to blaNDM-harbouring isolates in a Greek Tertiary Care Hospital","volume":"13","author":"Protonotariou","year":"2024","journal-title":"Antibiotics"},{"key":"B79","doi-asserted-by":"publisher","first-page":"e159","DOI":"10.1016\/S2666-5247(22)00329-9","article-title":"Global epidemiology and clinical outcomes of carbapenem-resistant Pseudomonas aeruginosa and associated carbapenemases (POP): a prospective cohort study","volume":"4","author":"Reyes","year":"2023","journal-title":"Lancet Microbe"},{"key":"B80","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/s40121-025-01147-w","article-title":"From clinical trials to real-world experiences: evidence about cefiderocol use and potential role in empirical therapy","volume":"14","author":"Russo","year":"2025","journal-title":"Infect. Dis. Ther."},{"key":"B81","doi-asserted-by":"publisher","author":"Sader","year":"","DOI":"10.1128\/AAC.00311-18"},{"key":"B82","doi-asserted-by":"publisher","first-page":"2400","DOI":"10.1093\/jac\/dky227","article-title":"Murepavadin activity tested against contemporary (2016\u201317) clinical isolates of XDR Pseudomonas aeruginosa","volume":"73","author":"Sader","year":"","journal-title":"J. Antimicrob. Chemother."},{"key":"B83","doi-asserted-by":"publisher","first-page":"e0383623","DOI":"10.1128\/spectrum.03836-23","article-title":"In vitro activity of cefiderocol against European Pseudomonas aeruginosa and Acinetobacter spp., including isolates resistant to meropenem and recent \u03b2-lactam\/\u03b2-lactamase inhibitor combinations","volume":"12","author":"Santerre Henriksen","year":"2024","journal-title":"Microbiol. Spectr."},{"key":"B84","doi-asserted-by":"publisher","first-page":"e0075122","DOI":"10.1128\/aac.00751-22","article-title":"Ceftazidime-avibactam plus aztreonam for the treatment of infections by VIM-type-producing gram-negative bacteria","volume":"66","author":"Sempere","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"B85","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","article-title":"Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis","volume":"18","author":"Tacconelli","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae403","article-title":"Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections","author":"Tamma","year":"2024","journal-title":"Clin. Infect. Dis."},{"key":"B87","doi-asserted-by":"publisher","first-page":"e01140","DOI":"10.1128\/JCM.01140-18","article-title":"Phenotypic detection of carbapenemase-producing organisms from clinical isolates","volume":"56","author":"Tamma","year":"2018","journal-title":"J. Clin. Microbiol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"e0131322","DOI":"10.1128\/aac.01313-22","article-title":"Infective endocarditis associated with implantable cardiac device by metallo-\u03b2-lactamase-producing Pseudomonas aeruginosa, successfully treated with source control and cefiderocol plus imipenem","volume":"67","author":"Tascini","year":"2023","journal-title":"Antimicrob. Agents Chemother."},{"key":"B89","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1080\/22221751.2022.2048972","article-title":"Carbapenemase-producing Pseudomonas aeruginosa\u2014an emerging challenge","volume":"11","author":"Tenover","year":"2022","journal-title":"Emerg. Microbes Infect."},{"key":"B90","doi-asserted-by":"publisher","first-page":"108581","DOI":"10.1016\/j.ijid.2026.108581","article-title":"Phage therapy in people with cystic fibrosis: a systematic review","volume":"167","author":"Terlizzi","year":"2026","journal-title":"Int. J. Infect. Dis"},{"key":"B91","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.ijantimicag.2014.12.033","article-title":"In vitro activity of ceftazidime, ceftaroline and aztreonam alone and in combination with avibactam against European gram-negative and Gram-positive clinical isolates","volume":"45","author":"Testa","year":"2015","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B92","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1093\/cid\/ciac078","article-title":"Cefiderocol for the treatment of infections due to metallo-B-lactamase-producing pathogens in the CREDIBLE-CR and APEKS-NP phase 3 randomized studies","volume":"75","author":"Timsit","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"B93","doi-asserted-by":"publisher","first-page":"106611","DOI":"10.1016\/j.ijantimicag.2022.106611","article-title":"Diagnosis and management of infections caused by multidrug-resistant bacteria: guideline endorsed by the Italian Society of Infection and Tropical Diseases (SIMIT), the Italian Society of Anti-Infective Therapy (SITA), the Italian Group for Antimicrobial Stewardship (GISA), the Italian Association of Clinical Microbiologists (AMCLI) and the Italian Society of Microbiology (SIM)","volume":"60","author":"Tiseo","year":"2022","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B94","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1007\/s10096-025-05108-6","article-title":"Effectiveness and safety of cefiderocol treatment in patients with gram-negative bacterial infections in Spain in the early access programme: results of the PERSEUS study","volume":"44","author":"Torre-Cisneros","year":"2025","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"B95","doi-asserted-by":"publisher","first-page":"e02874","DOI":"10.1128\/JCM.02874-20","article-title":"Antimicrobial susceptibility profiles to predict the presence of carbapenemase genes among carbapenem-resistant Pseudomonas aeruginosa isolates","volume":"59","author":"Vallabhaneni","year":"2021","journal-title":"J. Clin. Microbiol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"e04266","DOI":"10.1128\/spectrum.04266-23","article-title":"Resistance to ceftazidime\u2013avibactam and other new \u03b2-lactams in Pseudomonas aeruginosa clinical isolates: a multi-center surveillance study","volume":"12","author":"Valzano","year":"2024","journal-title":"Microbiol. Spectr."},{"key":"B97","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1002\/phar.70036","article-title":"Cefepime-taniborbactam: ushering in the era of metallo-\u03b2-lactamase inhibition","volume":"45","author":"Van Helden","year":"2025","journal-title":"Pharmacotherapy"},{"key":"B98","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s12866-025-03935-3","article-title":"Loss of OprD function is sufficient for carbapenem-resistance-only but insufficient for multidrug resistance in Pseudomonas aeruginosa","volume":"25","author":"Wang","year":"2025","journal-title":"BMC Microbiol."},{"key":"B99","doi-asserted-by":"publisher","first-page":"e01619","DOI":"10.1128\/AAC.01619-19","article-title":"A large-scale whole-genome comparison shows that experimental evolution in response to antibiotics predicts changes in naturally evolved clinical Pseudomonas aeruginosa","volume":"63","author":"Wardell","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"B100","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1089\/mdr.2022.0279","article-title":"In vitro activity of cefiderocol against meropenem-nonsusceptible gram-negative bacilli with defined \u03b2-lactamase carriage: SIDERO-WT surveillance studies, 2014\u20132019","volume":"29","author":"Wise","year":"2023","journal-title":"Microb. Drug Resist."},{"key":"B101","doi-asserted-by":"publisher","first-page":"614058","DOI":"10.3389\/fmicb.2021.614058","article-title":"Mobile carbapenemase genes in Pseudomonas aeruginosa","volume":"12","author":"Yoon","year":"2021","journal-title":"Front. Microbiol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.jgar.2025.05.023","article-title":"Epidemiological insights into global metallo-\u03b2-lactamases-producing Pseudomonas aeruginosa: a comprehensive analysis based on NCBI database","volume":"44","author":"Zhai","year":"2025","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"B103","doi-asserted-by":"publisher","first-page":"1619626","DOI":"10.3389\/fmicb.2025.1619626","article-title":"A comprehensive review of the pathogenic mechanisms of Pseudomonas aeruginosa: synergistic effects of virulence factors, quorum sensing, and biofilm formation","volume":"16","author":"Zhang","year":"2025","journal-title":"Front. Microbiol."}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2026.1924442\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T13:51:30Z","timestamp":1788529890000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2026.1924442\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,4]]},"references-count":103,"alternative-id":["10.3389\/fmicb.2026.1924442"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2026.1924442","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,4]]},"article-number":"1924442"}}